Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
NCT05753306

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Led by Mayo Clinic · Updated on 2026-04-08

40

Participants Needed

1

Research Sites

361 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This phase II clinical trial tests how well robotic cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in treating patients with gastric cancer that has spread to the tissue that lines the wall of the abdominal cavity (peritoneum). Gastric cancer is the third leading cause of cancer related deaths worldwide and peritoneal metastasis are found in 30% of patients at time of diagnosis. Patients with peritoneal metastasis have poor survival rates. Traditional surgery is done with a large incision and has a high complication rate and longer hospital stays. Robot assisted (robotic) cytoreduction is a surgical option that uses small incisions and there is less risk of complications. HIPEC involves infusing heated chemotherapy into the abdominal cavity during surgery. Robotic cytoreduction together with HIPEC may improve recovery and decrease complications after surgery.

CONDITIONS

Official Title

Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ages 18 to 80 years
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  • Histologic confirmation of gastric adenocarcinoma or Siewert type II/III gastroesophageal junction adenocarcinoma
  • Absolute neutrophil count of at least 1,500 / uL
  • Platelet count of at least 50,000 / uL
  • Serum creatinine level of 1.5 mg / dL or less
  • Adequate nutrition with albumin level of 3.5 or higher
  • Metastasis confined to the peritoneum confirmed by positive cytology, laparoscopy, or imaging
  • Response to systemic chemotherapy shown by tumor shrinkage, reduced standardized uptake value, decreased peritoneal carcinomatosis index, or lower serum tumor markers
  • Peritoneal Carcinomatosis Index (PCI) of 7 or less with expected complete cytoreduction
  • Body Mass Index (BMI) of 35 kg/m2 or less
Not Eligible

You will not qualify if you...

  • Distant metastases beyond the peritoneum, including liver, lung, bone, or distant lymph nodes
  • Presence of malignant ascites at study enrollment
  • Medical conditions that prevent receiving study treatment
  • Inability to comply with study or follow-up procedures
  • History of life-threatening or severe allergic reactions to the chemotherapy drugs used in this study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

Actively Recruiting

Loading map...

Research Team

C

Clinical Trials Referral Office

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here